Galapagos NV

Gilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do

After years of declining investor confidence in its business model, Galapagos is to start afresh by splitting in two and resetting its failed in-licensing deal with Gilead . The Belgium-based biote

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip ‘s global team, in this podcast version of Five Must-Know Things. This ep

Galapagos is to launch its first US-based clinical trial of its point-of-care CAR-T technology, which it hopes can be a game-changer in oncology. The novel CAR-T technology has been Galapagos’s brigh